Please refer to Phase I studies for more clinical trial opportunities.

**Melanoma**

**Stage 2b or 2c**
- IRB# 19679: Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study

**Stage 2b, 2c or 3**
- IRB# 11848: Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence

**Observational**
- IRB# 17104: DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study

**Uveal Melanoma**
- IRB# 16162: A Phase 1, Open-label, Study Evaluating Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are planned to Undergo Enucleation

**Stage 3 or 4 Resectable**
- IRB# 15661: A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipiilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma
- IRB# 16883: A Phase III, Randomized Study of Nivolumab with Ipiilimumab vs. Ipiilimumab or Nivolumab Monotherapy Post-resection
- Moderna: A Phase II randomized study of adjuvant Immunotherapy with Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

---

**CROSS-DISEASE TRIALS:**
- IRB# TBD: EAY131 (MATCH)
- IRB# TBD: S1609 (DART)

---

http://www.ohsu.edu/research/rda/so/knight.php

9/25/2019
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>IRB# 16198</td>
<td>A Phase 1 Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides</td>
</tr>
<tr>
<td>IRB# 18687</td>
<td>A phase 3, randomized, open-label study of NKTR-214 combined with nivolumab versus nivolumab in participants with previously untreated unresectable or metastatic melanoma.</td>
</tr>
<tr>
<td>IRB# 19207</td>
<td>A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)</td>
</tr>
<tr>
<td>IRB# 19943</td>
<td>A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab Alone in Patients with Previously Untreated Advanced Melanoma</td>
</tr>
<tr>
<td>IRB# 19285</td>
<td>A Phase 1b/2 Study of PV-10 Intratinal Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma</td>
</tr>
</tbody>
</table>

Please refer to Phase I studies for more clinical trial opportunities.

Melanoma

Stage 3 or 4, Unresectable

Mutation Specific

IRB# 19667
A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib+Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients with BRAFV600-Mutant Melanoma Brain Metastasis

Non-Mutation Specific

IRB# 16198
A Phase 1 Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides

IRB# 18687
A phase 3, randomized, open-label study of NKTR-214 combined with nivolumab versus nivolumab in participants with previously untreated unresectable or metastatic melanoma.

IRB# 19207
A Phase 3 Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)

IRB# 19943
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab Alone in Patients with Previously Untreated Advanced Melanoma

IRB# 19285
A Phase 1b/2 Study of PV-10 Intratinal Injection in Combination with Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma